Liver Disease Breakthrough: UCLA’s Radical Approach

Scientists working in a laboratory with microscopes and test tubes

UCLA scientists wiped out “zombie” immune cells in mice and reversed fatty liver damage without changing their diets, hinting at a radical fix for a disease plaguing millions.

Story Snapshot

UCLA team cleared senescent macrophages from diseased mouse livers using ABT-263, slashing liver size by 30-40% and body weight by 25%.
Zombie cells surged to 15-20% in aged, high-fat diet mice versus under 5% in young ones, driving inflammation and fat buildup.
Results showed healthier, redder livers instead of enlarged yellowish ones, reducing inflammaging independent of lifestyle.
NAFLD affects 30-40% of U.S. adults, higher in Latino communities; this targets root causes for potential human therapies.
ABT-263 toxic for humans; next steps screen safer senolytics.

UCLA Identifies Senescent Macrophages in Fatty Livers

UCLA researchers pinpointed senescent macrophages—zombie immune cells—that pile up in aging mouse livers fed high-fat, high-cholesterol diets. These cells, jumping from under 5% in young mice to 15-20% in diseased ones, spew inflammatory signals via senescence-associated secretory phenotype (SASP). High-fat diets and age trigger this buildup, modeling human metabolic dysfunction-associated steatotic liver disease (MASLD). Livers ballooned to 7% of body weight, turning yellowish and enlarged.

ABT-263, a senolytic drug and BCL-2 inhibitor, selectively killed these macrophages. Mice lost 25% body weight, dropping from 40g to 30g. Livers shrank to 4-5% body weight, regained red color, and showed less inflammation. No diet changes occurred; reversal stemmed purely from cell clearance. Lead researcher Salladay-Perez called the full reversal “wowing,” proving senolytics go beyond slowing disease.

Cellular Senescence Roots in 1960s, Senolytics Emerge Post-2015

Scientists described cellular senescence in the 1960s: cells halt division but linger, secreting SASP to inflame tissues. Post-2000s aging research spotlighted zombie cells in diseases. Senolytics arrived around 2015; navitoclax (ABT-263) tested in mice for age-related ills like kidney and lung issues. Aging plus high-fat diets spark macrophage senescence, fueling fat accumulation and fibrosis in livers.

Prior work complements UCLA’s. Mayo Clinic researchers in 2023-2025 linked mitochondrial RNA leaks to RIG-I/MDA5 sensors, igniting inflammation in MASH. Tulane studies used drugs to cut senescent cell-driven fat and scars in mice. UCLA’s novelty: macrophage-specific clearance reverses metabolic damage in NAFLD models, distinct from broader senescence efforts.

NAFLD Epidemic Hits 30% Globally, 50% in High-Risk Groups

Non-alcoholic fatty liver disease strikes 30% worldwide, up to 50% in Latino populations, tied to obesity, aging, and inflammaging. No approved drugs exist; lifestyle fixes often fail. UCLA’s April 16, 2026, Nature Aging paper used transgenic mice on junk diets to mimic human MASLD. Clearing zombies validated a root cause, spurring safer drug hunts despite ABT-263’s human toxicity.

Salladay-Perez emphasized: “Eliminating senescent cells doesn’t just slow the fatty liver—it actually reverses it.” UCLA targets LA’s 30-40% prevalence, seeking therapies bypassing diet struggles. Personal responsibility meets innovation, cutting healthcare burdens without mandating behavioral overhauls that ignore real-world limits.

Scientists remove “zombie” cells and reverse liver damage in mice https://t.co/wyE6pXrIZ1

— Beatrice Oki (@beatrice_oki) April 16, 2026

Short-term, preclinical validation accelerates senolytic R&D. Long-term, human-safe drugs could reverse liver disease and inflammaging broadly, slashing billions in costs. NAFLD patients and aging Americans stand to gain; pharma eyes macrophage targets, boosting firms like Unity Biotech. Socially, it counters obesity epidemics; politically, bolsters NIH funding for practical science.